(NYSE American: SER) Tops Our Watchlist This Morning — With Less Than 12M Shares Listed In Its Float And a Phase 1b Ahead of Schedule

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Serina Therapeutics, Inc. (NYSE American: SER) Just Landed On Our Watchlist This Morning —Wednesday, September 9, 2026… Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Consider Starting Your Own Research On (SER) While It’s Still Early… September 9, 2026 Dear Reader, The countdown to the opening bell is now under 90 minutes, and Serina Therapeutics, Inc. (NYSE American: SER) is moving to the top of our morning watchlist. With its small public float, advancing Parkinson’s program, and recent clinical progress, (NYSE American: SER) has several ingredients that could draw added attention today. When the global Parkinson's therapeutics sector is projected to grow from $8.38B in 2026 to more than $15B by 2034 — a compound annual growth rate near 8.2%, according to Fortune Business Insights — the names worth watching aren't necessarily the large-cap pharma companies that everyone already follows… They're the ones building something fundamentally different at the platform level. North America alone accounts for more than a third of the global Parkinson's therapeutics market, and the need for better-tolerated, longer-acting formulations has never been more clear… Serina Therapeutics, Inc. (NYSE American: SER) is one of those names. This Huntsville, Alabama-based clinical-stage biotechnology company has developed a proprietary polymer technology — the POZ Platform™ — designed to transform existing therapeutic compounds into optimized formulations that work longer, release more smoothly, and reduce the side-effect burden that often limits current treatments for neurological conditions. The company's lead candidate, SER-252, is a POZ-conjugated apomorphine now advancing through a Phase 1b registrational trial in patients with advanced Parkinson's disease… And the pace of execution around this company right now suggests the timeline could be accelerating. Serina Therapeutics, Inc. (NYSE American: SER) is topping our watchlist this morning—September 9, 2026. But keep in mind, (NYSE American: SER) has a float less than 12M listed as available to the public—with a float that small, the potential exists for big moves if demand begins to shift. And according to analyst consensus data, two analysts currently cover (SER) with bullish ratings. Thomas Shrader at BTIG holds a target of $8, while Justin Walsh at Jones carries a target of $11 — putting the average consensus at $9.50, which suggests more than 250% upside potential from the company's recent $2.70 range. What Makes the POZ Platform Different At its core, the POZ Platform™ is built on poly(2-oxazoline), a synthetic, water-soluble polymer engineered to give researchers greater control over how attached therapeutic agents are loaded and released into the body. The concept is straightforward but powerful… Many approved compounds that treat Parkinson's disease are effective but limited. Short half-lives force patients into dosing schedules that create peaks and valleys in the bloodstream. Narrow therapeutic windows mean too much of a compound causes toxicity, while too little leaves symptoms uncontrolled. And inconsistent blood levels contribute to the motor fluctuations and dyskinesia that make daily life so difficult for patients with advanced Parkinson's… Serina Therapeutics, Inc. (NYSE American: SER) is addressing those limitations head-on by conjugating proven active ingredients to its POZ polymer, creating formulations designed to maintain stable, sustained levels through subcutaneous delivery. The company's lead program, SER-252, is specifically designed to provide continuous dopaminergic stimulation — an approach shown to reduce the severity of levodopa-related motor complications in patients with advanced Parkinson's disease. Perhaps just as importantly, preclinical work supports the potential of SER-252 to deliver that stimulation without the skin reactions that have historically limited older infusion-based therapies. That distinction matters more than it might appear on the surface. Skin-site tolerability has been a persistent challenge for subcutaneous delivery systems in neurology. A compound that can provide continuous dopamine receptor activation without that barrier could represent a meaningful step forward for patients who have exhausted satisfactory oral options… And with Parkinson's patient numbers projected to rise substantially over the coming decade as populations age, the addressable market for a genuinely differentiated therapy in this space only grows from here. The platform's versatility extends well beyond a single compound. Serina has a second candidate, SER-214, a POZ-conjugated rotigotine targeting early Parkinson's and Restless Leg Syndrome, which has already completed a Phase 1a clinical evaluation. And the company holds a non-exclusive license agreement with Pfizer to use its POZ polymer technology in lipid nanoparticle delivery formulations — a validation of the platform's broader applicability across modalities including RNA-based therapeutics and antibody-based conjugates. That kind of large-pharma partnership around a delivery technology, even in a non-exclusive capacity, speaks to the underlying quality of what the POZ Platform™ can do… A Rapid-Fire Stretch of Milestones The past several months have been unusually dense with forward progress for (SER). In July 2026, the company completed enrollment and dosing of all eight patients in Cohort 1 of its Phase 1b registrational trial for SER-252 — ahead of the company's previously disclosed end-of-third-quarter guidance. That acceleration matters. In clinical-stage biotech, delivering milestones ahead of schedule signals operational discipline, strong site performance, and genuine demand from clinical researchers and patients willing to participate in the study… CEO Steve Ledger described the moment in direct terms: "The progression from sentinel group review to completion of dosing reflects strong execution by our clinical sites and study team," he stated in a July 2026 announcement. Top-line data from the single-ascending-dose arm of the registrational study is now targeted for the first half of 2027 — a near-term readout that could refocus attention on (SER) in a meaningful way. The trial itself is designed as a randomized, double-blind, placebo-controlled Phase 1b study with both single-ascending-dose and multiple-ascending-dose components, conducted across sites in the United States and Australia, with plans to expand to South Korea and Taiwan. Meanwhile, the company has been building out the infrastructure around its lead candidate. In June 2026, Serina Therapeutics, Inc. (NYSE American: SER) entered a development partnership with Gannet BioChem, a specialty CDMO with more than 30 years of expertise in activated polymers and complex therapeutic programs, to support process development, scale-up, and manufacturing for SER-252. Gannet BioChem's CEO called the partnership a fit, citing Serina's position at a stage where experienced manufacturing support becomes essential for continued progress. That same announcement confirmed that SER-252 had received FDA clearance of its Investigational New Compound application, enabling further advancement into clinical development… Then in July, Serina Therapeutics, Inc. (NYSE American: SER) appointed Farrell Simon, Pharm.D., to its Board of Directors. Simon currently serves as Chief Commercial Officer at Trevi Therapeutics, where he helped support financings totaling more than $400M from top-tier firms including Frazier, Vivo, Venrock, and Viking. Prior to Trevi, he spent a decade at Pfizer in senior commercial and strategic leadership roles. His background in commercial readiness, business development, and capital markets engagement adds a dimension that could become increasingly relevant as SER-252 progresses through later-stage development… The company ended Q2 2026 with $23M in cash and cash equivalents, providing a financial foundation to advance SER-252 through its ongoing clinical milestones. 9 Reasons Why We Have All Eyes On (SER) This Morning—Wednesday, September 9, 2026… 1. Small Float: with fewer than 12M shares listed as available to the public, SER’s small float could have the potential for big moves if demand begins to shift. 2. Analyst Targets: with BTIG carrying an $8 target and Jones with an $11 target, SER currently has two bullish analyst ratings with a $9.50 average across those published estimates. 3. Phase 1b: the lead candidate at SER, SER-252, is advancing through a randomized, double-blind, placebo-controlled Phase 1b registrational trial in advanced Parkinson's disease. 4. Early Execution: after completing enrollment and dosing for all eight Cohort 1 patients ahead of its previously disclosed end-of-Q3 guidance, SER has already delivered one key clinical milestone ahead of schedule. 5. 2027 Readout: top-line data from the single-ascending-dose portion of the SER-252 study are targeted for H1 2027, giving SER a defined future clinical milestone to follow. 6. POZ Platform: the proprietary poly(2-oxazoline) technology behind SER is designed to provide greater control over therapeutic loading and release through polymer conjugation. 7. Pfizer License: through a non-exclusive agreement with Pfizer covering potential use of POZ technology in lipid nanoparticle formulations, SER has established a relationship with one of the world's largest pharmaceutical companies. 8. Manufacturing Support: a June 2026 development partnership with Gannet BioChem gives SER specialized support for SER-252 process development, scale-up, and manufacturing. 9. Cash Position: after ending Q2 2026 with approximately $23M in cash and cash equivalents, SER reported financial resources available to support its ongoing clinical work. Consider Starting Your Own Research On (SER) While It’s Still Early… Serina Therapeutics, Inc. (NYSE American: SER) sits at the intersection of a massive and accelerating therapeutic market, a differentiated delivery platform, and a clinical timeline that just moved forward… The Parkinson's therapeutics sector continues to expand as the global population ages and demand for more tolerable, longer-acting treatments intensifies. This company — with a sub-12M share float, $23M in cash, a lead program hitting milestones ahead of schedule, a CDMO partnership securing its manufacturing path, new board-level commercial expertise, and analyst targets suggesting significant upside from current levels — could be a name that deserves a closer look. The pieces are assembling around a clinical-stage biotech that appears to be executing on every front that matters at this stage of development. And with a data readout from the single-ascending-dose arm coming in the first half of 2027, the next several months could be decisive for where it goes from here… We have all eyes on (SER) this morning. Consider taking a look at (SER) while it’s still early. Also, keep an eye out for my next update, it could be coming very shortly. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and SNT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between TD Media LLC and LFG Equities Corp., TD Media LLC has been hired for a period beginning on 09/08/2026 and ending on 09/09/2026 to publicly disseminate information about (SER:US) via digital communications. Under this agreement, LFG Equities Corp. has paid TD Media LLC fifty thousand USD (“Funds”). To date, including under the previously described agreement, TD Media LLC has been paid one hundred forty seven thousand five hundred USD (“Funds”). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named LFG Equities Corp. who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither TD Media LLC and their member own shares of (SER:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/ser-E8Asv/#details

TD Media LLC | 5826 New Territory Blvd., Unit #2144, Sugar Land, TX 77479 Unsubscribe About our service provider Sent by jeff@stocknewstrends.com